medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 5

<< Back Next >>

Med Int Mex 2023; 39 (5)

Distending pressure and its association with mortality in patients with severe acute respiratory distress syndrome due to COVID-19 in a third-level hospital in Northeast Mexico

Villalobos SJA, Flores DD, Quintanilla MIJ, Aguilera OOI, Martínez PHY

Language: Spanish
References: 43
Page: 752-759
PDF size: 231. Kb.


ABSTRACT

Objective: To evaluate distending pressure as a risk factor associated with mortality in patients with severe acute respiratory distress syndrome due to COVID-19.
Materials and Methods: A retrospective cohort association study was carried out in patients with severe acute respiratory distress syndrome due to COVID-19 hospitalized in the Intensive Care Unit of the High Specialty Regional Hospital of Ciudad Victoria Bicentenario 2010, Tamaulipas, Mexico. Records of patients who met the selection criteria were collected from April 1st, 2020 to February 1st, 2021. Non-probabilistic sampling was used for availability; as well as the clinical-epidemiological data collected.
Results: A total of 30 patients were included, of which the predominant sex was male (n = 17); the average age was 56.86 ± 11.6 years, the hospital stay was 12.36 ± 6.7 days. Regarding the association of mortality and distension pressure, a χ2 of 1.03 and a p = 0.460 were obtained and finally the distension pressure of the surviving patients was 14 mmHg.
Conclusions: Although the relationship between increased distension pressure and patient mortality was observed clinically, this relationship was not significant.


REFERENCES

  1. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y.Molecular diagnosis of a novel coronavirus (2019-nCoV)causing an outbreak of pneumonia. Clin Chem 2020; 66(4): 549-555. doi: 10.1093/clinchem/hvaa029.

  2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. Anovel coronavirus from patients with pneumonia in China,2019. N Engl J Med 2020; 382 (8): 727-733. doi: 10.1056/NEJMoa2001017.

  3. Coronaviridae Study Group of the International Committeeon Taxonomy of Viruses. The species severe acute respiratorysyndrome-related coronavirus: classifying 2019-nCoVand naming it SARS-CoV-2. Nat Microbiol 2020; 5 (4): 536-44. doi. org/10.1038/s41564-020-0695-z.

  4. WHO. WHO Director-General’s remarks at the mediabriefing on 2019-nCoV. 2020. https://www.who.int/dg/speeches/ detail/who-director-general-sremarks-at-themedia-briefing-on-2019-ncov-on-11-february-2020 (acceso04/02/2023).

  5. OMS. Alocución de apertura del Director General de la OMSen la rueda de prensa sobre la COVID-19 celebrada el 11de marzo de 2020. https://www.who.int/es/dg/speeches/detail/ who-director-general-s-openingremarks-at-themedia-briefing-on-covid-19---11-march-2020 (acceso04/02/2023).

  6. Prompetchara E, Ketloy C, Palaga T. Immune responses inCOVID-19 and potential vaccines: Lessons learned fromSARS and MERS epidemic. Asian Pac J Allergy Immunol2020; 38 (1): 1-9. doi.org/10.12932/AP-200220-0772.

  7. Ministerio de Sanidad. Centro de Coordinación de Alertasy Emergencias Sanitarias. Enfermedad por coronavirus,COVID-19. https://www.mscbs.gob. es/profesionales/saludPublica/ccayes/alertasActual/nCovChina/documentos/20200404_ITCoronavirus.pdf (acceso 13/02/2023).

  8. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesisof SARS-CoV2 infection-a review of immune changesin patients with viral pneumonia. Emerg Microbes Infect2020; 9 (1): 727-32. doi.org/10.1080/22221751.2020.1746199.

  9. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system.J Gastroenterol Hepatol 2020; 35 (5): 744-748. doi.org/10.1111/ jgh.15047.

  10. Siddiqi HK, Mehra MR. COVID-19 Illness in native andimmunosuppressed states: a clinical-therapeutic stagingproposal. J Heart Lung Transplant 2020; 39 (5): 405-407.doi.org/10.1016/j.healun.2020.03.012.

  11. Secretaría de Salud de México. Dirección General deEpidemiología. Comunicado Técnico diario.Disponible en: http://www.gob.mx/salud/documentos/coronaviruscovid-19 (acceso 13/02/2023).

  12. Escudero X, Guarner J, Galindo-Fraga A, Escudero-SalamancaM, Alcocer Gamba M. La pandemia de coronavirusSARS-CoV-2 (COVID-19): situación actual e implicacionespara México; Cardiovasc Metab Sci 2020; 31 (3): s170-s177.doi: 10.24875/ACM.M20000064.

  13. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND,Caldwell E, Fan E, Camporota L, Slutsky AS. Force ADT:Acute respiratory distress syndrome: The Berlin definition.JAMA 2012; 307: 2526-33 doi: 10.1001/jama.2012.5669.

  14. Williams GW, Berg N, Reskallah A, Yuan X, Eltzschig HK.Acute respiratory distress syndrome: Contemporary managementand novel approaches during COVID 19. Anesthesiology2021; 134 (2): 270-282. https://doi.org/10.1097/ALN.0000000000003571.

  15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B,Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H,Cao B. Clinical course and risk factors for mortality of adultinpatients with COVID-19 in Wuhan, China: A retrospectivecohort study. Lancet 2020; 395: 1054-62. doi: 10.1016/S0140-6736(20)30566-3

  16. McGonagle D, O’Donnell JS, Sharif K, Emery P, BridgewoodC. Immune mechanisms of pulmonary intravascular coagulopathyin COVID-19 pneumonia. Lancet Rheumatol2020; 2 (7): 437-45. doi: 10.1016/S2665-9913(20)30121-1.

  17. Teuwen LA, Geldhof V, Pasut A, Carmeliet P: COVID19: Thevasculature unleashed. Nat Rev Immunol 2020; 20 (7):389-91. doi: 10.1038/s41577-020-0343-0.

  18. Cao W, Li T: COVID-19: Towards understanding of pathogenesis.Cell Res 2020; 30 (5): 367-9. doi: 10.1038/s41422-020-0327-4.

  19. Pham T, Brochard L, Slutsky A. Mechanical ventilation:state of art. Mayo Clin Proc 2017; 92 (9): 1382-1400. doi:10.1016/j.mayocp.2017.05.004.

  20. Parker JC, Hernandez LA, Peevy KJ. Mechanisms of ventilator-induced lung injury. Crit Care Med 1993; 21 (1): 131-43.doi: 10.1097/00003246-199301000-00024.

  21. Tonetti T, Vasques F, Rapetti F, Maiolo G, Collino F, RomittiF, Camporota L, Cressoni M, Cadringher P, Quintel M, GattinoniL. Driving pressure and mechanical power: newtargets for VILI prevention. Ann Transl Med 2017; 5 (14):286. doi: 10.21037/atm.2017.07.08.

  22. Slutsky AS. History of mechanical ventilation: from Vesaliusto ventilator-induced lung injury. Am J Respir Crit Care Med2015; 191 (10): 1106-1115. doi: 10.1164/rccm.201503-0421PP.

  23. Vasques F, Duscio E, Cipulli F, Romitti F, Quintel M, GattinoniL. Determinants and prevention of ventilator-induced lunginjury. Crit Care Clin 2018; 34 (3): 343-356. doi: 10.1016/j.ccc.2018.03.004.

  24. Vaporidi K, Xirouchaki N, Georgopoulos D. Should wecare about driving pressure during assisted mechanicalventilation? J Intensive Crit Care 2017; 3 (2): 26. doi :10.21767/2471-8505.100085.

  25. Montoya-Zumaeta J, Cornejo-Rosas R. Driving Pressure,bases fisiológicas y aplicaciones clínicas. Rev Chilena MedIntens 2019; 34 (3).

  26. Dianti J, Matelski J, Tisminetzky M, Walkey AJ, MunshiL, Del Sorbo L, Fan E, Costa EL, Hodgson CL, Brochard L,Goligher EC. Comparing the effects of tidal volume, drivingpressure, and mechanical power on mortality in trials oflung-protective mechanical ventilation. Respir Care 2021;66 (2): 221-227. doi: 10.4187/respcare.07876.

  27. Amato MB, Meade MO, Slutsky AS. Driving pressureand survival in the acute respiratory distress syndrome.N Engl J Med 2015; 372 (8): 747-755. doi: 10.1056/NEJMsa1410639.

  28. Bellani G, Laffey JG, Pham T. LUNG SAFE Investigators;ESICM Trials Group. Epidemiology, patterns of care, andmortality for patients with acute respiratory distresssyndrome in Intensive Care Units in 50 countries. JAMA2016; 315 (8): 788-800. doi: 10.1001/ jama.2016.0291. 11.

  29. Pérez-Nieto OR, Deloya-Tomás E, Lomelí-Terán JM. Presiónde distensión (driving pressure): Principal objetivopara la protección alveolar. Neumol Cir Torax 2018; 77(3): 222-227.

  30. Suárez V, Suarez-Quezada M, Oros-Ruiz S, Ronquillo DeJesús E. Epidemiología de COVID-19 en México: del 27 defebrero al 30 de abril de 2020. Rev Clin Esp 2020; 220 (8):463-471. doi: 10.1016/j.rce.2020.05.007.

  31. Juárez Hernández F, García Benítez MP, Hurtado DuarteAM, Rojas Varela R, Farías Contreras JP, Pensado PiedraLE. Hallazgos tomográficos en afectación pulmonar porCOVID-19, experiencia inicial en el Instituto Nacional deEnfermedades Respiratorias Ismael Cosío Villegas, Ciudadde México. Neumol Cir Torax 2020; 79 (2): 71-77. https://doi.org/10.35366/94630.

  32. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C. Clinical characteristicsof 3062 COVID-19 patients: A meta-analysis. J Med Virol2020; 92 (10): 1902-1914. doi: 10.1002/jmv.25884.

  33. O’Driscoll M, Ribeiro Dos Santos G, Wang L. Age-specificmortality and immunity patterns of SARS-CoV-2. Nature2021; 590: 140-145. Doi: 10.1038/s41586-020-2918-0.

  34. Ejaz H, Alsrhani A, Zafar A, Javed H, et al. COVID-19 andcomorbidities: Deleterious impact on infected patients. JInfect Public Health 2020; 13 (12): 1833-39. doi: 10.1016/j.jiph.2020.07.014.

  35. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristicof patients dying in relation to COVID-19. JAMA2020; 323 (18): 1775-1776. doi: 10.1001/jama.2020.4683.

  36. Merad M, Martin J. Pathological inflammation in patientswith COVID-19: a key role formonocytes and macrophages.Nat Rev Immunol 2020; 20: 355-362. doi: 10.1038/s41577-020-0331-4.

  37. Huang C, Wang Y, Li X. Clinical features of patients infectedwith 2019 novel coronavirus in Wuhan, China. Lancet 2020;395: 497-506. doi: 10.1016/S0140-6736(20)30183-5.

  38. Fajgenbaum D, June C. Cytokine storm. N Engl J Med 2020;383: 2255-2273. doi: 10.1056/NEJMra2026131.

  39. Zirui M, Meng C, Rénia L. The trinity of COVID-19: immunity,inflammation and intervention. Nat Rev Immunol 2020; 20(6): 363-374. doi: 10.1038/s41577-020-0311-8.

  40. Cajamarca-Baron J, Guavita-Navarro D, Buitrago-BhorquezJ. SARS-CoV-2 (COVID-19) en pacientes con algún grado deinmunosupresión. Reumatol Clin 2021; 17 (7): 408-419.doi: 10.1016/j.reuma.2020.08.004.

  41. Nájera H, Ortega-Ávila AG. Health and institutional risk factorsof COVID-19 mortality in Mexico, 2020. Am J Prev Med2021; 60 (4): 471-477. doi: 10.1016/j.amepre.2020.10.015.

  42. Petrova D, Salamanca-Fernández E, Rodríguez M. La obesidadcomo factor de riesgo en personas con COVID-19:posibles mecanismos e implicaciones. Aten Primaria 2020;52 (7): 496-500. doi: 10.1016/j.aprim.2020.05.003.

  43. Gattinoni L, Pesenti A. The concept of “baby lung”. IntensiveCare Med 2005; 31 (6): 776-84.




2020     |     www.medigraphic.com